Lung Transplantation: a 4-year Single-centre Experience
분야
의약학 > 내과학
저자
( Jiwon Lyu ) , ( Seong Il Park ) , ( Dong Kwan Kim ) , ( Yong Hee Kim ) , ( Hyeong Ryul Kim ) , ( Se Hoon Choi ) , ( Tae Jin Yun ) , ( Sung Ho Jung ) , ( Tae Sun Shim ) , ( Sang Bum Hong ) , ( Jin Won Huh ) , ( Jae Young Moon ) , ( In Cheol Choi ) , ( Ky
발행기관
대한결핵 및 호흡기학회
간행물정보
대한결핵및호흡기학회 추계학술발표초록집 2012년, 제114권 216(총1페이지)
파일형식
0y909940.pdf [무료 PDF 뷰어 다운로드]
  • ※ 본 자료는 참고용 논문으로 수정 및 텍스트 복사가 되지 않습니다.
  • 구매가격
    1,000원
    적립금
    30원 (구매자료 3% 적립)
    이메일 발송  스크랩 하기
    자료 다운로드  네이버 로그인
    영문초록
    Objectives: Lung transplantation is currently the ultimate treatment option for patients with end-stage lung disease refractory to medical treatment. In reviewing our 4-year experience we sought to evaluate complications and survival after sequential bilateral lung transplantation. Methods: From October, 2008 to June, 2012, we performed 18 lung transplantation procedures. Underlying lung diseases were idiopathic pulmonary fibrosis in 6 patients; toxic inhalation injury in 5; post-bone marrow transplantation bronchiolitis obliterance in 3; acute respiratory distress syndrome in 2; lymphangioleiomyomatosis in 1, and angiosarcoma in 1. Data for all patients were collected and analyzed retrospectively. Procedures were carried out using standardized protocols. Results: Thirteen patients underwent double lung and five heart-lung transplantations. Among them, 12 patients (66.7%) underwent high-emergency lung transplantation. Early complications were prolonged air leak, vocal cord palsy, critical illness polyneuropathy, necrotizing pancreatitis, and renal failure requiring dialysis. Late complications consisted of airway complications (n=6), gastro-intestinal complications (n=7), diabetes mellitus (n=2), osteopenia (n=2), and post-transplantation lymphoproliferative disorders (n=1). There was no peri-operative death. Two patients (11.1%) died from 6 and 8 months after lung transplantation, because of the infection. Conclusion: We conclude that lung transplantation is a viable option for selected patients with end-stage lung disease refractory to medical treatment.
    사업자등록번호 220-87-87785 대표.신현웅 주소.서울시 서초구 방배로10길 18, 402호 대표전화.070-8809-9397
    개인정보책임자.박정아 통신판매업신고번호 제2017-서울서초-1765호 이메일 help@reportshop.co.kr
    copyright (c) 2009 happynlife. steel All reserved.